N,N'-bis(2,2,6,6-tetramethyl-4-piperidyl)isophthalamide

Genetic toxicity: in vitro

Administrative data

Endpoint:

in vitro gene mutation study in mammalian cells

Remarks:

Type of genotoxicity: gene mutation

Type of information:

experimental study

Adequacy of study:

key study

Study period:

2012

Reliability:

1 (reliable without restriction)

Rationale for reliability incl. deficiencies:

other: Guideline conform GLP study

Data source

Reference

Reference Type:

study report

Title:

Unnamed

Year:

2012

Report date:

2012

Materials and methods

Test guideline

Test guideline 1

Qualifier:

according to guideline

Guideline:

OECD Guideline 476 (In Vitro Mammalian Cell Gene Mutation Test)

Deviations:

no

Test guideline 2

Qualifier:

according to guideline

Guideline:

EU Method B.17 (Mutagenicity - In Vitro Mammalian Cell Gene Mutation Test)

Deviations:

no

Test guideline 3

Qualifier:

according to guideline

Guideline:

EPA OPPTS 870.5300 - In vitro Mammalian Cell Gene Mutation Test

Deviations:

no

GLP compliance:

yes (incl. QA statement)

Type of assay:

mammalian cell gene mutation assay

Test material

Test material information

Constituent 1

Test material form:

other: solid

Method

Species / strain

Species / strain / cell type:

mouse lymphoma L5178Y cells

Details on mammalian cell type (if applicable):

- Type and identity of media:
Complete culture medium: RPMI 1640 supplemented with 10% horse serum, 100 µg/mL penicillin/streptomycin, 1 mM sodium pyruvate, 2 mM L-glutamine, 25 mM HEPES, 2.5 µg/mL amphotericin B
Treatment medium: RPMI 1640 supplemented with 5-7.5% horse serum, 100 µg/mL penicillin/streptomycin, 1 mM sodium pyruvate, 2 mM L-glutamine, 25 mM HEPES, 2.5 µg/mL amphotericin B
Selctive medium: RPMI 1640 supplemented with 20% horse serum, 100 µg/mL penicillin/streptomycin, 1 mM sodium pyruvate, 2 mM L-glutamine, 25 mM HEPES, 2.5 µg/mL amphotericin B, 5 µg/mL TFT
- Properly maintained: yes
- Periodically checked for Mycoplasma contamination: yes

Metabolic activation:

with and without

Metabolic activation system:

S9 mix

Test concentrations with justification for top dose:

Experiment I
with and without S9 mix: 0.2, 0.5, 1.0, 2.5, 5.0, 7.5, 9.0 and 10.0 mM
Experiment II
with S9 mix: 0.3, 0.6, 1.2, 2.4, 3.0, 7.0, 8.0, 9.5 and 10.0 mM
without S9 mix: 0.2, 0.5, 1.0, 2.5, 4.0, 5.0, 6.0 and 7.0 mM

Vehicle / solvent:

cell culture medium (RPMI 1640 + 5% horse serum)

Controls

Negative solvent / vehicle controls:

yes

Positive controls:

yes

Positive control substance:

benzo(a)pyrene

ethylmethanesulphonate

methylmethanesulfonate

Details on test system and experimental conditions:

METHOD OF APPLICATION:
For a short term exposure experiment 1x10(exp7) were suspended in 11 mL RPMI medium with 5% horse serum and exposed to designated concentrations of the test item either in the presence or absence of metabolic activation in the mutation experiment. After 4 h the test item was removed by centrifugation.
For a long term exposure experiment 5x10(exp6) were suspended in 25 mL RPMI medium with 7.5% horse serum and exposed to designated concentrations of the test item in the absence or presence of metabolic activation. After 24 h the test item was removed by centrifugation.

DURATION
- Exposure duration: 4 and 24 h
- Expression time (cells in growth medium): 2 days
- Selection time (if incubation with a selection agent): 14 days

SELECTION AGENT (mutation assays): Trifluorothymidine (TFT)

NUMBER OF REPLICATIONS: experiments with 8 different dose levels

DETERMINATION OF CYTOTOXICITY
- Method: (relative) suspension growth; (relative) clonin efficiency

Evaluation criteria:

The test item is considered mutagenic if following criteria are met:
- The induced mutant frequency meets or exceeds the Global Evaluation factor (GEF) of 126 mutants per 10(exp6) cells
- A dose-dependent increase in mutant is detected.
Besides, combined with a positive effect in the mutant frequency, an increased occurrence of small colonies (>/= 40% of total colonies) is an indication for potential clastogenic effects and/or chromosomal aberrations.
According to the OECD guideline, the biological relevance is considered first for the interpreatation of results. Statisitcal methods might be used as an aid in evaluation the test result. A test item is considered to be negative if the induced mutant frequency is below the GEF and the trend is negative.

Statistics:

non-parametric Mann-Whitney test

Results and discussion

Test results

Species / strain:

mouse lymphoma L5178Y cells

Metabolic activation:

with and without

Genotoxicity:

negative

Cytotoxicity / choice of top concentrations:

cytotoxicity

Vehicle controls validity:

valid

Positive controls validity:

valid

Additional information on results:

No precipitation of the test item was observed in the experiments.

No growth inhibition was noted in the pre experiment and in experiment I with and without metabolic activation and in experiment II with metabolic activation. Growth inhibition was observed in pre experiment II and in experiment II without metabolic activation.
In experiment I with metabolic activation the relative total growth (RTG) was 141.2% for the highest concentration (10mM) evaluated. The highest concentration evaluated without metabolic activation was 10 mM with a RTG of 78.7%. In experiment II with metabolic activation the relative total growth (RTG) was 115.7% for the highest concentration (10 mM) evaluated. The highest concentration evaluated without metabolic activation was 7 mM with a RTG of 16.3%.

In experiment I and II no biologically relevant increase of mutants was found after treatment with the test item (with and without metabolic activation). The Global Evaluation Factor (GEF) was not exceeded by the induced mutant frequency at any concentration.
No dose-response relationship was observed. Additionally, in experiment I and II colony sizing showed no clastogenic effects induced by the test item under the xperimental conditions (with and without metabolic activation).

EMS, MMs and B[a]P were used as positive controls and showed distinct and biologically relevant effects in mutation frequency. Addtionally, MMS and B[a]P significantly increased the number of small colonies, thus proving the efficiency of the test system to indicate potential clastogenic effects.

Remarks on result:

other: all strains/cell types tested

Remarks:

Migrated from field 'Test system'.

Applicant's summary and conclusion

Conclusions:

Interpretation of results (migrated information):
negative with metabolic activation
negative without metabolic activation

In the described mutagenicity test (MLA) under the experimental conditions reported, the test item is considered to be non-mutagenic in the in vitro mammalian cell gene mutation assay (thymidine kinase locus) in mouse lymphoma L5178Y cells.

Executive summary:

The test item N,N’-Bis(2,2,6,6-tetramethyl-4-piperidinyl)isophthalamide was assessed for its potential to induce mutations at the mouse lymphoma kinase locus using the cell line L5178Y.

The selection of the concentrations used in the main experiments was based on data fro the pre experiments. In experiment I 10 mM (with and without metabolic activation) was selected as the highest concentrations. In experiments II 10 mM (with metabolic activation) and 7 mM (without metabolic activation) were selected as the highest concentrations. Experiment I with and without metabolic activation and experiment II with metabolic activation were performed as a 4 h short term exposure assay. Experiment II without metabolic activation was perfomed as a 24 h long term exposure assay.

The test item was investigated at the following concentrations:

Experiment I

with and without metabolic activation: 0.2, 0.5, 1.0, 2.5, 5.0, 7.5, 9.0 and 10.0 mM

Experiment II

with metabolic activation: 0.3, 0.6, 1.2, 2.4, 3.0, 7.0, 8.0, 9.5 and 10.0 mM

and without metabolic activation: 0.2, 0.5, 1.0, 2.5, 4.0, 5.0, 6.0 and 7.0 mM.

No precipitation of the test item was observed in the experiments.

No growth inhibition was noted in the pre experiment and in experiment I with and without metabolic activation and in experiment II with metabolic activation. Growth inhibition was observed in pre experiment II and in experiment II without metabolic activation.

In experiment I with metabolic activation the relative total growth (RTG) was 141.2% for the highest concentration (10mM) evaluated. The highest concentration evaluated without metabolic activation was 10 mM with a RTG of 78.7%. In experiment II with metabolic activation the relative total growth (RTG) was 115.7% for the highest concentration (10 mM) evaluated. The highest concentration evaluated without metabolic activation was 7 mM with a RTG of 16.3%.

In experiment I and II no biologically relevant increase of mutants was found after treatment with the test item (with and without metabolic activation). The Global Evaluation Factor (GEF) was not exceeded by the induced mutant frequency at any concentration.

No dose-response relationship was observed. Additionally, in experiment I and II colony sizing showed no clastogenic effects induced by the test item under the xperimental conditions (with and without metabolic activation).

EMS, MMs and B[a]P were used as positive controls and showed distinct and biologically relevant effects in mutation frequency. Addtionally, MMS and B[a]P significantly increased the number of small colonies, thus proving the efficiency of the test system to indicate potential clastogenic effects.